Clinical trials located in

Verona

Verona city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Verona, nestled in northern Italy’s Veneto region, is a city steeped in history and culture. Known as the setting for Shakespeare’s “Romeo and Juliet,” it boasts the well-preserved ancient Roman Arena, which now hosts regular opera performances. The city’s medieval old town is woven with cobbled streets, leading to the picturesque Piazza delle Erbe. Verona is also recognized as a UNESCO World Heritage Site, a testament to its rich architectural heritage and vibrant history that spans over two millennia.

  • CT-EU-00120654

    Study of Barzolvolimab (CDX-0159) in Adult Patients with Eosinophilic Esophagitis

    This clinical study involves patients with Eosinophilic Esophagitis (EoE), a condition where a type of white blood cell, called eosinophils, builds up in the lining of the esophagus. This can lead to difficulty swallowing and other issues. The therapy being tested is barzolvolimab (CDX-0159).

    The goal of the study is to test the effectiveness and safety of barzolvolimab in adults with active EoE. There are two main groups in this study: one will receive barzolvolimab, and the other will receive a placebo, followed by barzolvolimab.

    Participants will receive treatment through subcutaneous (under the skin) injections every four weeks for 24 weeks. In the barzolvolimab group, patients will get 300 mg of the medication from the start. In the other group, patients will receive a placebo for the first 16 weeks and then switch to barzolvolimab for the remaining 8 weeks.

    The study will look at changes in the number of eosinophils and other cells in the esophagus, as well as symptoms like difficulty swallowing. Side effects and other health changes will be monitored throughout the study.

    • Placebo
    • barzolvolimab
  • Study WVE-003 in patients with early-stage Huntington’s disease

    This clinical trial is a study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a new drug called WVE-003 in adult patients with early Huntington’s disease (HD). WVE-003 is a type of drug designed to target specific genetic sequences. In this case, it is targeting a single nucleotide polymorphism (SNP), known as SNP3, in Huntington’s disease patients. The drug is administered intrathecally, i.e., it is injected into the spinal canal.

    The study is double-blind, meaning neither patients nor researchers know who is receiving the actual drug and who is receiving the placebo. This helps ensure the results are impartial. The primary goal is to evaluate the safety of WVE-003 by monitoring the percentage of patients who experienced adverse events from day 1 to the end of the study, which lasts a minimum of 36 weeks.

    • WVE-003
  • Clinical Trial for Finding the Best Dose of Clodronate for Painful Knee Osteoarthritis

    Howdy there, folks! This here clinical trial is aimin’ to find the best dose of a medicine called clodronate for treatin’ painful knee arthritis. It’s gonna be split into two parts.

    In the first part, they’ll have four groups of folks with knee arthritis. Three of them groups will get different doses of clodronate injected right into their knee once a week for four weeks. The fourth group will get a placebo, which is like a fake medicine. They’ll be keepin’ an eye on how safe and tolerable them different doses are.

    Once they figure out which dose works best without too many side effects, they’ll move on to the second part. In that part, they’ll have two groups – one gettin’ the best dose of clodronate from the first part, and the other gettin’ a placebo again. They’ll be checkin’ to see how effective and safe that best dose really is for helpin’ with knee arthritis pain.

    The main thing they’re lookin’ for is if the clodronate can reduce knee pain by at least 10 millimeters on a special pain scale called the Visual Analogue Scale, compared to the placebo group. They’ll be measurin’ that around 7 weeks into the study.

    So in a nutshell, they’re tryin’ to find the best and safest dose of clodronate for helpin’ folks with painful knee arthritis. It’s a two-part study, and they’ll be keepin’ a close eye on how well it works and how well it’s tolerated.

    • Clodronate
    • placebo
  • To evaluate the effectiveness of nivolumab used alone and in combination with HBI-8000 in the treatment of unresectable or metastatic melanoma

    This is a study comparing two treatment options for patients with melanoma that cannot be surgically removed or has spread to other parts of the body. One treatment option is an investigational drug called Tucidinostat (HBI-8000) taken by mouth twice a week in combination with an approved drug called nivolumab given by intravenous infusion. Another option is a placebo taken orally twice a week, also in combination with nivolumab given by intravenous infusion.

    The primary goal of the study is to determine whether the combination of HBI-8000 and nivolumab is more effective than nivolumab alone in shrinking the tumor or preventing further tumor progression. The study will also assess the safety of the treatment combinations.

    Patients enrolled in the main study will be randomly assigned to receive either the HBI-8000 combination or a placebo combination. Treatment will continue for up to 2 years or until the cancer progresses, side effects worsen or the patient decides to withdraw from the study. The study will last up to 4 years and will include regular monitoring and follow-up visits.

    • Placebo
    • Tudicdinostat/HBI-8000
  • Study on the Safety and Effectiveness of INCB057643 for Myelofibrosis and Other Myeloid Neoplasms

    This clinical trial is focused on evaluating the safety, tolerability, and initial effectiveness of a medication called INCB057643, either on its own or in combination with another drug known as ruxolitinib. It is designed for participants who are dealing with myelofibrosis or other advanced myeloid neoplasms, which are types of blood disorders. The study aims to understand how well participants can handle the treatment and to observe any potential benefits or side effects that may occur during the trial. The treatment’s impact will be measured by monitoring the number of treatment-related adverse events, which includes any new or worsening symptoms following the start of the medication. This study is an important step towards finding new treatment options for individuals with myelofibrosis and related conditions, offering hope for better management of these diseases.

    • INCB057643
    • Ruxolitinib
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Study of belzutifan for treating advanced cancers

    This clinical trial aim is to test out a new drug called belzutifan, also known as MK-6482 or WELIREG™. It’s a pill patient can take once a day, and the main goal is to see if it can shrink or get rid of tumors in folks with certain types of cancer.

    The cancers the researchers are looking at are pheochromocytoma and paraganglioma, which are tumors that start in the adrenal glands or nervous system. Pancreatic neuroendocrine tumors, tumors related to von Hippel-Lindau disease, advanced gastrointestinal stromal tumors, and other solid tumors with certain genetic changes that involve a protein called HIF-2α, there will be also tested.

    The big thing the researchers are  keeping an eye on is the objective response rate, which means how many folks see their tumors shrink or disappear completely while taking this drug. The researchers will be watching closely for any side effects too, of course, to make sure this new medicine is safe.

    • Belzutifan
  • Ceralasertib & durvalumab vs docetaxel in advanced lung cancer study

    This is an open-label study titled LATIFY, which means everyone will know the type of treatment they are receiving. The study team is looking into a specific type of lung cancer, called Non-Small Cell Lung Cancer (NSCLC) which did not get better after previous treatments. Two treatments will be tested, a new combination of ceralasertib plus durvalumab, compared to a commonly used treatment, docetaxel. Doctors will track participants’ health over time to see which treatment helps people live longer. Understanding the results will help doctors responsibly give the best treatment for patients with this type of lung cancer.

    • Ceralasertib
    • Durvalumab
    • Docetaxel
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    • levoleucovorin
    • leucovorin
    • Fluorouracil
    • Bevacizumab
    • Cetuximab
    • Tucatinib
    • Oxaliplatin
    • Trastuzumab
  • Advanced lung cancer treatment: comparing osimertinib with standard chemotherapy

    In this extended study, researchers are evaluating two treatment approaches for non-small cell lung cancer (NSCLC), focusing on patients who have experienced disease progression extracranially after initial treatment with osimertinib. The study aims to compare the efficacy and safety of chemotherapy combined with osimertinib versus chemotherapy combined with a placebo. Patients are randomly assigned to one of two groups. Group A receives osimertinib daily along with two chemotherapy drugs (cisplatin or carboplatin and pemetrexed) for four 21-day cycles. After these cycles, they continue taking osimertinib with maintenance pemetrexed. Group B follows a similar protocol but with a placebo instead of osimertinib. The study’s objective is to understand which treatment method better helps patients with this specific cancer profile, considering factors like genetic mutations and the presence of brain metastases. By observing the treatment’s impact on disease progression and patient safety, the researchers hope to gain insights that could improve NSCLC treatment strategies.

    • AZD9291 (Osimertinib)
    • Cisplatin
    • Carboplatin
    • Pemetrexed
  • Understanding trastuzumab deruxtecan treatment for advanced lung cancer

    This study is testing a new lung cancer treatment, Trastuzumab Deruxtecan, to see if it’s effective and safe for patients with a certain type of advanced lung cancer (Non-Small Cell Lung Cancer with HER2 mutations). Patients in the study either receive this new treatment or standard care (cisplatin or carboplatin + pembrolizumab + pemetrexed). The main goal is to see if the new treatment helps patients live longer without their cancer getting worse and to monitor any side effects.

    • Trastuzumab deruxtecan
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    • GSK3511294 (Depemokimab)
    • Mepolizumab
    • Benralizumab
  • Study on the benefits of combined therapy for high-risk non-muscle invasive bladder cancer

    This research study is focused on investigating the safety and effectiveness of a medication called Pembrolizumab (MK-3475) when combined with Bacillus Calmette-Guerin (BCG) treatment in individuals with high-risk bladder cancer that has not spread to the muscle. The study involves two groups of patients: those who have not responded well to BCG alone and those who have not received BCG previously. For the first group, the primary objective is to determine if the combination of Pembrolizumab and BCG is more effective than BCG alone in eliminating their cancer. For the second group, the goal is to assess whether the combination therapy improves the likelihood of survival without any cancer-related events compared to BCG alone.

    • Bacillus Calmette-Guerin/BCG
    • Pembrolizumab
  • Research on using new therapy for treating advanced tumors

    This research is about a new medicine named INCB123667. It may help people who have serious cancers that have spread to other parts of the body. The trial has two parts. Part 1 will find out the best dose to use and if it causes any side effects. Part 2 will see if the medicine helps shrink the cancer cells. Doctors will check for side effects the first time the medicine is given. If side effects are severe, the medicine dose will be reduced. The timing of when the drug is given may also need to be changed. Doctors will measure the highest amount of the drug in the blood and how fast it reaches this level. They’ll also see how long it stays in the system and how quickly the body gets rid of it. Successful treatment would mean the cancer stops growing or shrinks.

    • INCB0123667- new potential medication for advanced malignancies
  • Testing new medication for advanced or spread-out solid tumors

    This research study is about checking if a new medicine, known as INCA33890, is safe for people who have advanced or metastatic solid tumors. This trial is important because it needs to be checked if this medicine can work safely without causing too much trouble or side effects for the person taking it. An important part of this trial is also to figure out how much of this medicine can be given safely to a person, so it helps to treat their cancer but doesn’t make them sick from the treatment itself.

    • INCA33890- new potential medication for solid tumors
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    • Teriflunomide
    • Remibrutinib
  • Pralsetinib vs regular care in treating advanced lung cancer

    This study is looking at how effective a medication called Pralsetinib is in treating a type of lung cancer called RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer. This cancer type is difficult to treat and usually spreads to other parts of the body. The medicine will be compared to the usual treatments given for this type of cancer. Doctors want to see if Pralsetinib can slow down or stop the cancer progression and how long that lasts. Any side effects experienced by patients will be carefully monitored to understand the medication’s safety.

    • Pralsetinib
    • Gemcitabine
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • nab-Paclitaxel
    • Paclitaxel
  • Evaluating epilepsy treatment with brivaracetam

    This study aims to see how effective and safe a drug called Brivaracetam is for children and young adults aged between 2 and 25 who have a type of epilepsy known as Absence Epilepsy. Brain activity will be recorded for 24 hours using a device on day 14. If the patient has not had an episode of epilepsy in the 4 days before the recording or during it, they are considered ‘free’ of seizures. If the patients experience a seizure, it will be recorded on the machine and these patients have to leave the study. These patients also should not be taking a type of drug known as benzodiazepine during the study. All people taking part will have to keep a diary of their seizures from the start of the study until the end.

    • Brivaracetam
  • Long-term safety evaluation of luspatercept treatment

    The study focuses on patients with myeloproliferative neoplasms. It tests the drug Luspatercept (ACE-536), evaluating its safety and efficacy over a long term compared to a placebo. This study assessing the prolonged safety of luspatercept in individuals previously enrolled in luspatercept studies. The trial involves multiple phases, including an initial assessment and a follow-up period, where the effects of Luspatercept on the disease’s progression and symptoms are closely monitored. This helps determine if the drug can significantly improve the condition or quality of life for those affected by these neoplasms.

    • Luspatercept
  • Secukinumab study for maintaining remission in axial spondyloarthritis

    The aim of this study is to see if a drug called Secukinumab can maintain remission in people with non-radiographic axial spondyloarthritis (a type of spondylitis). Remission means that there is no or very little disease in the body. To determine whether a person is in remission, we use a special scoring system that looks at various symptoms of arthritis and a blood test for a protein associated with inflammation (C-reactive protein, or CRP). The aim of the study is to see whether people who stop taking Secukinumab will experience an exacerbation (worsening of the disease) and how long it takes for this to happen. The study will last just over two years.

    • Secukinumab

See more clinical trials in other cities in Italy:

.